Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

PRTA

Prothena Corporation plc

Feb 13 • 04:00PM ET

8.96

+0.11 1.24 %

Healthcare • Biotechnology • Ireland • NASD

Peers: VRTX BIIB ALNY IONS SRPT NBIX EXEL ACAD ARWR CLDX

| Held by: XBI IWM VXF IWN IBB VTWO SCHA DFAS VHT FSCC

Index	RUT	P/E	-	EPS (ttm)	-5.21	Insider Own	19.39%	Shs Outstand	53.83M	Perf Week	0.56%
Market Cap	482.32M	Forward P/E	15.04	EPS next Y	0.60	Insider Trans	0.00%	Shs Float	43.39M	Perf Month	-2.61%
Enterprise Value	160.56M	PEG	0.61	EPS next Q	-0.56	Inst Own	81.55%	Short Float	16.28%	Perf Quarter	-17.42%
Income	-280.46M	P/S	40.91	EPS this Y	-106.80%	Inst Trans	1.96%	Short Ratio	11.94	Perf Half Y	11.17%
Sales	11.79M	P/B	1.64	EPS next Y	112.69%	ROA	-59.18%	Short Interest	7.06M	Perf YTD	-6.18%
Book/sh	5.48	P/C	1.46	EPS next 5Y	24.74%	ROE	-67.63%	52W High	16.67 -46.23%	Perf Year	-35.49%
Cash/sh	6.15	P/FCF	-	EPS past 3/5Y	- -3.15%	ROIC	-93.12%	52W Low	4.32 107.41%	Perf 3Y	-83.40%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-12.33% 178.00%	Gross Margin	69.05%	Volatility	4.49% 5.55%	Perf 5Y	-60.79%
Dividend TTM	-	EV/Sales	13.62	EPS Y/Y TTM	-112.24%	Oper. Margin	-1885.68%	ATR (14)	0.48	Perf 10Y	-71.56%
Dividend Ex-Date	-	Quick Ratio	6.61	Sales Y/Y TTM	-91.16%	Profit Margin	-2379.59%	RSI (14)	46.38	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.61	EPS Q/Q	38.12%	SMA20	-2.45%	Beta	-0.25	Target Price	20.33
Payout	-	Debt/Eq	0.03	Sales Q/Q	148.97%	SMA50	-5.52%	Rel Volume	0.49	Prev Close	8.85
Employees	163	LT Debt/Eq	0.02	Earnings	Nov 06 AMC	SMA200	6.62%	Avg Volume	591.84K	Price	8.96
IPO	Dec 21, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.03% -63.62%	Trades		Volume	290,008	Change	1.24%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-25	Downgrade	BofA Securities	Neutral → Underperform	$4
May-27-25	Downgrade	Oppenheimer	Outperform → Perform
May-27-25	Downgrade	Jefferies	Buy → Hold	$6
May-27-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-20-24	Initiated	Chardan Capital Markets	Buy	$40
Jan-30-24	Downgrade	BofA Securities	Buy → Neutral	$68 → $38
Dec-12-23	Initiated	Deutsche Bank	Buy	$62
Apr-24-23	Initiated	SVB Securities	Outperform	$80
Jan-27-23	Initiated	Piper Sandler	Overweight	$94
Nov-04-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$52 → $55
Sep-28-22	Upgrade	BofA Securities	Neutral → Buy
Nov-19-21	Initiated	JMP Securities	Mkt Outperform	$77
Jun-18-21	Upgrade	BofA Securities	Underperform → Neutral	$12 → $49
Jun-08-21	Reiterated	Oppenheimer	Outperform	$45 → $54
May-26-21	Initiated	Citigroup	Buy	$39
Feb-26-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$14 → $28
Feb-12-21	Upgrade	Jefferies	Hold → Buy	$15 → $30
Feb-02-21	Upgrade	BTIG Research	Neutral → Buy	$29
Dec-07-20	Initiated	H.C. Wainwright	Buy	$22
Jul-09-20	Upgrade	Oppenheimer	Perform → Outperform	$16

Show Previous Ratings

Feb-13-26 11:40AM	FTRE vs. PRTA: Which Stock Is the Better Value Option? (Zacks)
Feb-12-26 04:05PM	Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 (Business Wire)
Jan-21-26 12:00PM	All You Need to Know About Prothena (PRTA) Rating Upgrade to Buy (Zacks)
Jan-07-26 08:06AM	Fortrea Holdings Inc. (FTRE) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Dec-12-25 04:05PM	Prothena Announces Board of Directors Update (Business Wire)
04:05PM	Loading…
Nov-19-25 04:05PM	Prothena Announces Poster Presentation on its TDP-43 CYTOPE Program at Neuroscience 2025 (Business Wire)
Nov-11-25 09:00AM	Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA (Business Wire)
Nov-07-25 10:32AM	Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus (Zacks)
Nov-06-25 05:45PM	Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:46PM	Prothena: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Third Quarter 2025 Financial Results and Business Highlights (Business Wire)
Oct-30-25 04:05PM	Prothena to Report Third Quarter 2025 Financial Results on November 6 (Business Wire)
Oct-22-25 03:33PM	Prothena Corporation plc (PRTA): A Bull Case Theory (Insider Monkey)
Oct-01-25 04:45PM	Prothenas Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimers Disease (Business Wire)
Sep-11-25 10:01AM	Prothena Down 40% Year to Date: What Lies Ahead for the Stock? (Zacks)
11:30AM	Loading…
Sep-03-25 11:30AM	Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-28-25 04:05PM	Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference (Business Wire)
Aug-27-25 04:05PM	Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program (Business Wire)
Aug-08-25 05:07AM	Elevidys sales weaken; Neumora gets into obesity (BioPharma Dive)
Aug-06-25 09:00AM	Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy (Business Wire) +12.66%
Aug-04-25 05:50PM	Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:47PM	Prothena: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Second Quarter 2025 Financial Results and Business Highlights (Business Wire)
Jul-30-25 10:01AM	PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains? (Zacks)
Jul-29-25 10:00AM	Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline (Zacks)
Jul-28-25 04:05PM	Prothena to Report Second Quarter 2025 Financial Results on August 4 (Business Wire)
Jul-24-25 10:46AM	Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well (Zacks)
Jul-17-25 01:07PM	AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies (Zacks)
Jul-04-25 01:51PM	PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects? (Zacks)
Jun-20-25 07:22AM	Prothena to lay off majority of staff; Zealand shares obesity drug data (BioPharma Dive)
04:05PM	Loading…
Jun-18-25 04:05PM	Prothena Announces Corporate Restructuring (Business Wire)
Jun-17-25 01:30PM	Roche's Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA) (Insider Monkey)
09:16AM	Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus (TipRanks)
Jun-16-25 10:22AM	Roche, waving off study failures, commits to Phase 3 trials for Parkinsons drug (BioPharma Dive) +11.42%
09:49AM	RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development (Zacks)
01:06AM	Prothenas Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease (Business Wire)
May-29-25 03:40PM	Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails (Insider Monkey)
May-28-25 01:55PM	Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform (Insider Monkey)
May-27-25 01:08PM	Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results (Insider Monkey) -30.40%
10:20AM	Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down (Zacks)
07:53AM	Biogen strikes RNAi deal with City; Aurion withdraws IPO (BioPharma Dive)
07:43AM	Why Is Prothena Stock Trading Lower On Tuesday? (Benzinga)
May-26-25 06:16AM	Prothenas Phase III trial for AL amyloidosis treatment misses endpoint (Clinical Trials Arena)
May-23-25 04:05PM	Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint (Business Wire) -30.40%
May-09-25 01:28PM	Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025 (Zacks)
08:29AM	Is Prothena Corporation plc (PRTA) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-08-25 05:50PM	Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:47PM	Prothena: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
May-07-25 12:44PM	Prothena Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 04:05PM	Prothena to Report First Quarter 2025 Financial Results on May 8 (Business Wire) -5.22%
Apr-16-25 11:49AM	Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi (Zacks)
Feb-21-25 02:15AM	Prothena Corp PLC (PRTA) Q4 2024 Earnings Call Highlights: Strong Financial Position Amidst ... (GuruFocus.com)
Feb-20-25 05:25PM	Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:22PM	Prothena: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights (Business Wire)
Feb-13-25 04:05PM	Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 (Business Wire)
Dec-30-24 04:05PM	Prothena Announces Board of Directors Update (Business Wire) -6.92%
Dec-19-24 04:22PM	Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease (Investor's Business Daily) +33.97%
08:09AM	Prothenas Parkinsons study fails primary endpoint despite some success (Clinical Trials Arena)
01:05AM	Roches Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinsons Disease (Business Wire)
Dec-12-24 11:30AM	Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report? (Zacks)
Nov-12-24 05:55PM	Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:56PM	Prothena: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire)
Nov-05-24 04:05PM	Prothena to Report Third Quarter 2024 Financial Results on November 12 (Business Wire) +8.71%
Oct-29-24 12:00PM	Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
04:48AM	Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength? (Zacks)
Oct-18-24 03:01PM	State Street Corp's Strategic Reduction in Prothena Corp PLC Holdings (GuruFocus.com)
Sep-27-24 04:05PM	Prothena Announces Leadership Team Updates (Business Wire) -16.56%
Aug-29-24 04:05PM	Prothena to Participate in Upcoming Healthcare Conferences (Business Wire)
Aug-19-24 12:00PM	What Makes Prothena (PRTA) a New Buy Stock (Zacks)
Aug-18-24 12:28AM	Prothena Corporation plc (PTRA): Positioning Among Top Debt-Free Stocks (Insider Monkey)
Aug-17-24 08:22AM	7 Best Debt Free Stocks To Buy (Insider Monkey)
Aug-09-24 09:16AM	Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues (Zacks)
Aug-08-24 06:40PM	Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates (Zacks)
05:33PM	Prothena: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire)
Aug-01-24 04:05PM	Prothena to Report Second Quarter 2024 Financial Results on August 8 (Business Wire) -5.20%
Jul-25-24 10:02AM	Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jun-24-24 08:48AM	Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last? (Zacks)
Jun-11-24 04:07PM	Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower (Investor's Business Daily)
12:20PM	Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win (Investor's Business Daily)
Jun-07-24 11:30AM	Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report? (Zacks)
May-29-24 10:26AM	Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate (Zacks)
08:46AM	BMS stakes $80m on Prothenas neurodegenerative candidate (Pharmaceutical Technology)
May-28-24 04:05PM	Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration (Business Wire)
May-09-24 11:52AM	Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses (Zacks)
May-08-24 10:56PM	PRTA Stock Earnings: Prothena Corp Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:10PM	Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
05:14PM	Prothena: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
May-01-24 04:05PM	Prothena to Report First Quarter 2024 Financial Results on May 8 (Business Wire) +5.31%
Apr-25-24 10:01AM	Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline (Zacks)
Apr-15-24 04:05PM	Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma (Business Wire)
Mar-28-24 08:00AM	Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback (Investor's Business Daily)
Mar-05-24 04:05PM	Prothena to Participate in Upcoming Healthcare Conferences (Business Wire)
Mar-04-24 04:05PM	Prothena Appoints David Ford to Newly Created Chief People Officer Position (Business Wire)
Feb-21-24 04:05PM	Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate (Business Wire)
Feb-16-24 01:33PM	Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense (Zacks)

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EcoR1 Capital, LLC	10% Owner	May 02 '25	Sale	8.36	3,317,938	27,744,929	8,266,342	May 06 07:06 PM
EcoR1 Capital, LLC	10% Owner	May 06 '25	Sale	7.64	1,984,053	15,164,712	5,304,596	May 06 07:06 PM
EcoR1 Capital, LLC	10% Owner	May 05 '25	Sale	8.11	977,693	7,930,166	7,288,649	May 06 07:06 PM

Open in Screener

RARE

Ultragenyx Pharmaceutical Inc

Feb 13 • 04:00PM ET

20.52

-2.98 -12.68 %

Healthcare • Biotechnology • USA • NASD

RARE Ultragenyx Pharmaceutical Inc daily Stock Chart

Peers: BIIB VRTX ALNY BMRN AMGN REGN IONS CRSP NBIX PBYI

| Held by: VTI XBI VB VBK VXF IBB IWP SCHA IWF IWR

Index	-	P/E	-	EPS (ttm)	-5.84	Insider Own	6.94%	Shs Outstand	96.48M	Perf Week	-16.92%
Market Cap	1.98B	Forward P/E	-	EPS next Y	-0.89	Insider Trans	-0.30%	Shs Float	89.85M	Perf Month	-14.75%
Enterprise Value	2.11B	PEG	-	EPS next Q	-1.37	Inst Own	99.73%	Short Float	10.12%	Perf Quarter	-38.80%
Income	-575.44M	P/S	2.94	EPS this Y	29.10%	Inst Trans	3.96%	Short Ratio	3.64	Perf Half Y	-29.27%
Sales	672.72M	P/B	215.68	EPS next Y	78.38%	ROA	-37.91%	Short Interest	9.10M	Perf YTD	-10.78%
Book/sh	0.10	P/C	2.69	EPS next 5Y	-	ROE	-656.54%	52W High	46.27 -55.65%	Perf Year	-52.85%
Cash/sh	7.64	P/FCF	-	EPS past 3/5Y	16.78% -13.72%	ROIC	-72.42%	52W Low	18.41 11.46%	Perf 3Y	-53.16%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	22.81% 19.95%	Gross Margin	83.85%	Volatility	7.56% 5.17%	Perf 5Y	-86.34%
Dividend TTM	-	EV/Sales	3.14	EPS Y/Y TTM	7.91%	Oper. Margin	-79.63%	ATR (14)	1.47	Perf 10Y	-62.53%
Dividend Ex-Date	-	Quick Ratio	1.74	Sales Y/Y TTM	20.08%	Profit Margin	-85.54%	RSI (14)	30.16	Recom	1.19
Dividend Gr. 3/5Y	- -	Current Ratio	1.89	EPS Q/Q	7.37%	SMA20	-13.77%	Beta	0.16	Target Price	56.05
Payout	-	Debt/Eq	-	Sales Q/Q	25.55%	SMA50	-25.38%	Rel Volume	2.88	Prev Close	23.50
Employees	1294	LT Debt/Eq	-	Earnings	Feb 12 AMC	SMA200	-34.52%	Avg Volume	2.50M	Price	20.52
IPO	Jan 31, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-18.07% 4.23%	Trades		Volume	7,194,308	Change	-12.68%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$65
Jul-28-25	Resumed	H.C. Wainwright	Buy	$80
May-28-25	Initiated	William Blair	Outperform
Jun-06-24	Upgrade	Goldman	Neutral → Buy	$56 → $67
Apr-22-24	Initiated	RBC Capital Mkts	Outperform	$77
Dec-08-23	Initiated	Wells Fargo	Overweight	$72
Jun-14-23	Resumed	Credit Suisse	Outperform	$96
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform	$60 → $80
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight	$114
Jan-18-23	Resumed	Canaccord Genuity	Buy	$90
Dec-30-22	Resumed	H.C. Wainwright	Buy	$82
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform	$50
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$50
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line	$95 → $60
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform	$99 → $105
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight	$132
Sep-30-21	Initiated	H.C. Wainwright	Buy	$106
Aug-19-21	Initiated	UBS	Sell	$73
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy	$162

Show Previous Ratings

Feb-14-26 01:29AM	Ultragenyx (RARE) Announces Positive Long-Term Clinical Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A (Insider Monkey)
Feb-13-26 01:21PM	Why Is Ultragenyx Stock Sinking Friday? (Benzinga) -12.68%
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
08:30AM	Ultragenyx Pharmaceutical Inc. Q4 2025 Earnings Call Summary (Moby)
05:08AM	Ultragenyx cuts jobs as it seeks path to profit in 2027 (BioPharma Dive)
12:02AM	Loading…
12:02AM	Ultragenyx Pharmaceutical Inc (RARE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Feb-12-26 08:14PM	Ultragenyx Pharmaceutical Q4 Earnings Call Highlights (MarketBeat)
06:00PM	Ultragenyx (RARE) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:18PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update (GlobeNewswire)
Feb-09-26 03:30AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Feb-07-26 03:33AM	Ultragenyx Pharmaceutical (RARE) Resubmits Biologics License Application for Gene Therapy Treatment (Insider Monkey)
Feb-06-26 07:40AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights RARE (Business Wire)
Feb-05-26 04:05PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update (GlobeNewswire)
10:00AM	Loading…
10:00AM	Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-03-26 12:58PM	Ultragenyx Says Gene Therapy Shows Lasting Benefits, Slows Brain Decline In Fatal Childhood Disorder (Benzinga)
08:00AM	Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA) (GlobeNewswire)
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks)
Jan-30-26 08:30AM	Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA (GlobeNewswire)
Jan-23-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:05PM	Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies (PR Newswire)
Jan-21-26 04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
Jan-12-26 10:11AM	Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery (Insider Monkey) +8.26%
07:30AM	Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference (GlobeNewswire)
Jan-09-26 03:16AM	Analysts Lower Ultragenyx (RARE) Target but Stay Bullish (Insider Monkey)
Jan-07-26 04:05PM	Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.36%
Jan-05-26 03:56AM	Novo launches Wegovy pill; Argenx to swap CEOs (BioPharma Dive)
Dec-31-25 09:50AM	RARE Rises on Completion of Rolling Submission for AAV Gene Therapy (Zacks)
09:40AM	DigitalBridge downgraded, Commvault initiated: Wall Streets top analyst calls (TipRanks)
09:01AM	Loading…
09:01AM	Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last? (Zacks)
07:37AM	Ultragenyx (RARE) Rockets 15.5% on Bargain-Hunting After Steep Fall (Insider Monkey)
Dec-30-25 04:31PM	Stocks Fall Slightly in Thin Holiday Trade (Barchart) +15.52%
04:05PM	Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
03:58PM	Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today (Motley Fool)
12:39PM	Why Ultragenyx Stock Dropped 42% and What Comes Next (Barrons.com)
11:06AM	Stocks Slip as Bond Yields Rise (Barchart)
11:00AM	RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint (Zacks)
09:36AM	DigitalBridge downgraded, Commvault initiated: Wall Street's top analyst calls (The Fly)
08:11AM	Company News for Dec 30, 2025 (Zacks)
06:17AM	S&P Futures Tread Water Ahead of FOMC Meeting Minutes (Barchart)
Dec-29-25 04:21PM	These Stocks Moved the Most Today: Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More (Barrons.com) -42.32%
03:34PM	Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today (Motley Fool)
01:18PM	These Stocks Are Moving the Most Today: Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More (Barrons.com)
01:05PM	These biotech stocks are getting hammered by shocking brittle-bone treatment study results (MarketWatch)
08:30AM	Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta (GlobeNewswire)
Dec-19-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-11-25 07:44AM	Is Ultragenyx Pharmaceutical Inc. (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Dec-04-25 11:30AM	Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-28-25 11:57AM	Barclays Remains Cautious on Ultragenyx (RARE), Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook (Insider Monkey)
Nov-24-25 04:30PM	Ultragenyx to Participate in Investor Conferences in December (GlobeNewswire)
Nov-21-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.73%
Nov-10-25 08:19PM	Morgan Stanley Reaffirms "Buy" Rating on Ultragenyx Pharmaceutical (RARE) with $55 PT (Insider Monkey)
Nov-05-25 10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
12:10AM	Ultragenyx Pharmaceutical Inc (RARE) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Nov-04-25 05:30PM	Here's What Key Metrics Tell Us About Ultragenyx (RARE) Q3 Earnings (Zacks)
05:15PM	Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:13PM	Ultragenyx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
04:01PM	Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita (burosumab) for $400 Million to OMERS Life Sciences (GlobeNewswire)
Oct-30-25 08:00AM	Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups (GlobeNewswire)
Oct-29-25 10:00AM	Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-28-25 04:30PM	Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
10:00AM	Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-24-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.31%
Oct-17-25 09:16AM	Strength Seen in DBV Technologies (DBVT): Can Its 6.8% Jump Turn into More Strength? (Zacks)
Oct-08-25 12:57AM	Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Oct-03-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-25 09:45AM	Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline (Insider Monkey)
Sep-30-25 04:05PM	Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President (GlobeNewswire)
04:00AM	Cantor Fitzgerald Reiterates a Buy Rating on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Sep-29-25 08:28AM	FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza (Zacks)
Sep-19-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-16-25 09:17AM	Is Ultragenyx Pharmaceutical (RARE) a Compelling Long-Term Opportunity? (Insider Monkey)
Sep-10-25 11:11AM	IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome (Zacks)
Sep-09-25 11:12AM	RARE Reports Positive Long-Term Data From Metabolic Disorder Study (Zacks)
Sep-08-25 04:05PM	Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
Aug-29-25 04:30PM	Ultragenyx to Participate at Investor Conferences in September (GlobeNewswire) +6.91%
Aug-21-25 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-18-25 08:00AM	Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
Aug-06-25 11:43AM	Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
03:29AM	Ultragenyx Pharmaceutical Inc (RARE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Aug-05-25 05:30PM	Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:06PM	Ultragenyx: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
Aug-04-25 03:32PM	Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory (Insider Monkey)
Jul-31-25 04:05PM	Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome (GlobeNewswire)
11:35AM	Ultragenyx Pharmaceutical Inc. (RARE) Gets FDA CRL for UX111, Vows Quick Resubmission (Insider Monkey)
10:00AM	Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline (Zacks)
Jul-30-25 08:30AM	Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
Jul-24-25 11:09AM	BioHarvest Sciences Inc. (BHST) Surges 5.6%: Is This an Indication of Further Gains? (Zacks)
Jul-22-25 10:05AM	FDA Rejects Replimunes Skin Cancer Treatment, Shares Sink (Bloomberg)
Jul-18-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-17-25 10:38AM	Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Jul-16-25 09:38AM	William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
07:00AM	New Pedestrian Access from Inner Belt to East Somerville MBTA Station Now Open to the Public (PR Newswire)
Jul-15-25 08:28AM	Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA (Zacks) -6.94%
05:46AM	Health Canada extends Evkeeza approval for children with HoFH (Pharmaceutical Technology)
Jul-14-25 04:24PM	Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejection (Investor's Business Daily)
08:00AM	Health Canada Extends the Approval of Evkeeza (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Horn Howard	Chief Financial Officer	Feb 02 '26	Sale	23.56	3,061	72,117	88,935	Feb 03 12:00 PM
HOWARD HORN	Officer	Feb 02 '26	Proposed Sale	23.56	3,061	72,117		Feb 02 04:09 PM
Horn Howard	Chief Financial Officer	Jan 02 '26	Sale	22.84	3,150	71,946	91,996	Jan 05 04:07 PM
HOWARD HORN	Officer	Jan 02 '26	Proposed Sale	22.84	3,150	71,946		Jan 02 04:10 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Dec 29 '25	Sale	34.38	85	2,922	50,450	Dec 30 01:49 PM
Horn Howard	Chief Financial Officer	Dec 10 '25	Sale	36.38	3,081	112,087	95,146	Dec 11 12:10 PM
HOWARD HORN	Officer	Dec 10 '25	Proposed Sale	36.38	3,081	112,087		Dec 10 04:05 PM
Horn Howard	Chief Financial Officer	Oct 13 '25	Sale	31.51	7,942	250,252	98,227	Oct 14 12:15 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 18 '25	Sale	29.17	64	1,867	50,242	Sep 19 06:23 PM
KARAH PARSCHAUER	Officer	Sep 12 '25	Proposed Sale	31.17	2,450	76,366		Sep 12 04:17 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Sep 12 '25	Sale	31.17	2,450	76,366	73,271	Sep 12 04:11 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 05 '25	Sale	31.39	84	2,637	50,306	Sep 08 02:01 PM
Sanders Corazon (Corsee) D.	Director	Jun 20 '25	Sale	37.39	2,405	89,923	15,344	Jun 23 01:50 PM
CORAZON D. SANDERS	Director	Jun 20 '25	Proposed Sale	37.39	2,405	89,923		Jun 20 04:02 PM
Crombez Eric	EVP and Chief Medical Officer	May 05 '25	Sale	39.24	520	20,405	71,530	May 05 07:18 PM
Crombez Eric	EVP and Chief Medical Officer	Apr 21 '25	Sale	35.11	242	8,497	71,680	May 05 07:18 PM
Horn Howard	Chief Financial Officer	Mar 06 '25	Sale	40.40	1,785	72,114	106,169	Mar 10 12:53 PM
Kassberg Thomas Richard	CBO & EVP	Mar 03 '25	Sale	42.10	6,028	253,779	265,238	Mar 04 08:19 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 03 '25	Sale	42.10	12,846	540,817	75,287	Mar 04 08:18 PM
Crombez Eric	EVP and Chief Medical Officer	Mar 03 '25	Sale	42.10	8,945	376,584	71,922	Mar 04 08:16 PM
Pinion John Richard	See Remarks	Mar 03 '25	Sale	42.10	14,439	607,882	107,766	Mar 04 08:12 PM
KAKKIS EMIL D	President & CEO	Mar 03 '25	Sale	42.10	73,434	3,091,571	641,731	Mar 04 08:10 PM
KAKKIS EMIL D	President & CEO	Feb 28 '25	Sale	42.48	25,000	1,062,000	2,158,985	Mar 04 08:10 PM
Harris Erik	EVP & Chief Commercial Officer	Mar 03 '25	Sale	42.10	15,103	635,836	87,855	Mar 04 08:06 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Mar 03 '25	Sale	42.10	967	40,711	50,265	Mar 04 08:00 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Feb 27 '25	Sale	42.88	2,990	128,224	54,991	Mar 03 01:58 PM
KAKKIS EMIL D	Officer	Feb 28 '25	Proposed Sale	42.48	25,000	1,062,100		Feb 28 04:11 PM
Parschauer Karah Herdman	Officer	Feb 27 '25	Proposed Sale	42.88	2,990	128,215		Feb 27 05:08 PM

PRTA

Prothena Corporation plc

RARE

Ultragenyx Pharmaceutical Inc

Upgrade your FINVIZ experience